{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:17:00Z","timestamp":1759565820094},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00432-008-0488-x","type":"journal-article","created":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T12:53:43Z","timestamp":1222779223000},"page":"551-557","source":"Crossref","is-referenced-by-count":16,"title":["Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum\/taxane regimens as first-line therapy"],"prefix":"10.1007","volume":"135","author":[{"given":"Shin","family":"Nishio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kouno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Kamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kasamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,1]]},"reference":[{"key":"488_CR1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","volume":"59","author":"G Blackledge","year":"1989","unstructured":"Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650\u2013653","journal-title":"Br J Cancer"},{"key":"488_CR2","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21:149s\u2013167s","journal-title":"J Clin Oncol"},{"key":"488_CR3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/gyno.2002.6748","volume":"86","author":"KA Donovan","year":"2002","unstructured":"Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 86:200\u2013211","journal-title":"Gynecol Oncol"},{"key":"488_CR4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.2001.19.5.1266","volume":"19","author":"C Doyle","year":"2001","unstructured":"Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266\u20131274","journal-title":"J Clin Oncol"},{"key":"488_CR5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","volume":"8","author":"EA Eisenhauer","year":"1997","unstructured":"Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963\u2013968","journal-title":"Ann Oncol"},{"key":"488_CR6","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","volume":"38","author":"J Engel","year":"2002","unstructured":"Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Holzel D (2002) Moderate progress for ovarian cancer in the last 20\u00a0years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38:2435\u20132445","journal-title":"Eur J Cancer"},{"issue":"Suppl","key":"488_CR21","first-page":"16S","volume":"23","author":"MK Findley","year":"2005","unstructured":"Findley MK, Lee H, Seiden MV, Shah MA, Fuller AF, Goodman A, Penson RT (2005) Do more lines of chemotherapy make you live longer? Treatment for ovarian cancer comparing cohorts of patients 1989-90 with 1995-6 in multivariate analysis of survival. J Clin Oncol 23(Suppl):16S","journal-title":"J Clin Oncol"},{"key":"488_CR7","first-page":"104","volume":"23","author":"MF Fung","year":"2002","unstructured":"Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B (2002) Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum\u2014a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol 23:104\u2013110","journal-title":"Eur J Gynaecol Oncol"},{"key":"488_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15\u201336","journal-title":"CA Cancer J Clin"},{"key":"488_CR9","first-page":"107","volume":"6","author":"AP Heintz","year":"2001","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the ovary. J Epidemiol Biostat 6:107\u2013138","journal-title":"J Epidemiol Biostat"},{"key":"488_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","volume":"53","author":"A Jemal","year":"2003","unstructured":"Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003. CA Cancer J Clin 53:5\u201326","journal-title":"CA Cancer J Clin"},{"key":"488_CR11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/gyno.1998.4997","volume":"69","author":"M Markman","year":"1998","unstructured":"Markman M (1998) \u2018\u2018Recurrence within 6\u00a0months of platinum- therapy\u2019\u2019: an adequate definition of \u2018\u2018platinum-refractory\u2019\u2019 ovarian cancer? Gynecol Oncol 69:91\u201392","journal-title":"Gynecol Oncol"},{"key":"488_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389\u2013393","journal-title":"J Clin Oncol"},{"key":"488_CR13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s004320050177","volume":"124","author":"M Markman","year":"1998","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1998) Evidence that a \u2018\u2018treatment-free interval of less than 6\u00a0months\u2019\u2019 does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 124:326\u2013328","journal-title":"J Cancer Res Clin Oncol"},{"key":"488_CR14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141","journal-title":"J Clin Oncol"},{"key":"488_CR15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22045","volume":"107","author":"RP Rocconi","year":"2006","unstructured":"Rocconi RP, Case AS, Staughn JM Jr, Estes JM, Partridge EE (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effective analysis. Cancer 107:536\u2013543","journal-title":"Cancer"},{"key":"488_CR16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1048-891X.2004.014512.x","volume":"12","author":"S Tangjitgamol","year":"2004","unstructured":"Tangjitgamol S, See HT, Manusirvithaya S, Levenback CF, Gershenson DM, Kavanagh JJ (2004) Third-line chemotherapy in platinum-and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 12:804\u2013814","journal-title":"Int J Gynecol Cancer"},{"key":"488_CR17","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.2820710422","volume":"71","author":"JT Thigpen","year":"1993","unstructured":"Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559\u20131564","journal-title":"Cancer"},{"key":"488_CR18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","volume":"12","author":"JT Thigpen","year":"1994","unstructured":"Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 12:1748\u20131753","journal-title":"J Clin Oncol"},{"key":"488_CR19","first-page":"373","volume":"79","author":"A Villa","year":"1999","unstructured":"Villa A, Parazzini F, Scarfone G, Guarnerio P, Bolis G (1999) Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients. Br J Cancer 79:373\u2013374","journal-title":"Br J Cancer"},{"key":"488_CR20","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","volume":"19","author":"KM Zanotti","year":"2001","unstructured":"Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, Peterson G, Markman M (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126\u20133129","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-008-0488-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0488-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:39:49Z","timestamp":1559083189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-008-0488-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s00432-008-0488-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}